Tyler M. Seibert

Germline polygenic score for prostate cancer aggressiveness

This paper develops a germline polygenic score (PRSagg) to predict prostate cancer aggressiveness and validates it across multiple datasets.

Association of HOXB13 G84E with prostate cancer among 592,158 men

This paper shows the HOXB13 p.G84E variant increases prostate cancer risk by threefold in men, but does not lead to more aggressive cancer.

VADEr: Vision Transformer-Inspired Framework for Polygenic Risk Reveals Underlying Genetic Heterogeneity in Prostate Cancer

VADEr, a Vision Transformer-inspired framework, improves polygenic risk prediction for prostate cancer by capturing genetic interactions and revealing heterogeneity through DARTH scores.

From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study

The paper develops a polygenic risk model for prostate cancer using VA data and validates it in external cohorts, showing its clinical utility in risk stratification.

Multivariate genome-wide association study identifies 780 unique genetic loci associated with cortical morphology.

The paper uses a multivariate GWAS approach to identify 780 genetic loci associated with cortical morphology, showing a 10-fold increase in loci compared to univariate methods.

Prostate cancer risk stratification improved across multiple ancestries with new polygenic hazard score

The paper improves prostate cancer risk stratification across multiple ancestries using a new polygenic hazard score with additional SNPs, showing higher hazard ratios and positive predictive value for clinically significant prostate cancer.

Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24

The paper assesses how the performance of an African-ancestry-specific polygenic hazard score varies with local ancestry in 8q24 using genetic data from 6,253 men with African ancestry.

Common genetic and clinical risk factors: Association with fatal prostate cancer in the Cohort of Swedish Men

This study evaluates if adding polygenic hazard scores to clinical variables improves association with fatal prostate cancer in the Cohort of Swedish Men.

Polygenic hazard score is associated with prostate cancer in multi-ethnic populations

This study evaluates a polygenic hazard score in multi-ethnic populations and finds it is associated with age at prostate cancer diagnosis, aggressive diagnosis, and death across European, Asian, and African ancestries.

Additional SNPs improve the performance of a polygenic hazard score for prostate cancer

This study improves a polygenic hazard score for prostate cancer by adding 120 SNPs, enhancing hazard ratios but not positive predictive value of PSA testing.

African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer

The paper improves a polygenic hazard score for prostate cancer age at diagnosis by adding SNPs specific to African ancestry, enhancing performance in this population.

The effect of sample size on polygenic hazard models for prostate cancer

This paper evaluates how sample size affects polygenic hazard score models for prostate cancer, finding that 20-30k samples are needed for discovery models, but 10k suffice if SNPs are pre-established.

A genetic hazard score to personalize prostate cancer screening, applied to population data

The paper evaluates a polygenic hazard score for prostate cancer screening, showing it improves positive predictive value by adjusting screening age based on genetic risk.

A genetic risk score to guide age-specific, personalized prostate cancer screening

This paper develops a genetic risk score to personalize prostate cancer screening age based on polygenic hazard scores and validates its predictive power in a separate dataset.